---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Dosage"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Dosage. Topics: Recommended starting dosage by age, Upward titration and maximum dosage by weight, Dosage modifications for hearing loss: audiology schedule, Dosage titration recommendations based on audiology results, and 2 further topics. 6 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/dosage"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Dosage

<a id="heading-2.1.2.10.1"></a>

## 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

### Recommended starting dosage by age

> “Recommended starting LEMBAZ dosage in patients who weigh 7 kg or greater is the following (2.2):”
> “Less than 6 months of age is 100 mg every two weeks.”
> “6 months of age to less than 4 years of age is 200 mg every two weeks.”
> “4 years of age or older is 400 mg every two weeks.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.10.1-2"></a>

### Upward titration and maximum dosage by weight

> “See Table 1 for the recommended starting dosage and the recommended maximum dosage for LEMBAZ in patients who weigh 7 kg or greater.”
> “After at least 2 doses at each dosage level (a dosage level consists of the same dose of LEMBAZ given two weeks apart), titrate the LEMBAZ dosage upward in 100-mg to 200-mg increments as tolerated, up to the maximum recommended dosage.”
> “If 7 kg to less than 12 kg, maximum dosage is 600 mg every two weeks.”
> “If 12 kg or more, maximum dosage is 900 mg every two weeks.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

> “Lembaz dosing schedule: 1 intrathecal bolus injection every 2 weeks”
> “Give at least 2 doses at each dosage level, then step up as tolerated to the weight-based maximum, each step guided by audiology.”

Source: [LEMBAZ dosing and administration guide (2026)](https://lembazrx.com/wp-content/uploads/dosing-administration-guide.pdf)

<a id="topic-2.1.2.10.1-3"></a>

### Dosage modifications for hearing loss: audiology schedule

> “During LEMBAZ treatment to determine the subsequent dosage level, repeat the comprehensive audiology evaluation 1 to 2 weeks after the first LEMBAZ dose at each dosage level but before the next dose, and then 1 to 2 weeks after the second LEMBAZ dose at each dosage level but before the next dose (see Table 2).”
> “When a patient remains at the same LEMBAZ dosage level for 2 consecutive doses or has reached the maximum dosage, perform comprehensive audiology evaluations at one-month intervals until 3 consecutive, stable audiology results are obtained, and then repeat the comprehensive audiology evaluation every 12 months.”
> “In patients with LEMBAZ-associated hearing impairment, there are insufficient data to determine if continuing LEMBAZ treatment at the current dosage level increases the risk of further hearing impairment or if lowering the LEMBAZ dosage reduces the risk of further hearing impairment”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.10.1-4"></a>

### Dosage titration recommendations based on audiology results

| Baseline hearing status | Result permitting an increase (first criterion) | Result permitting an increase (alternative criterion) | Result precluding an increase |
| --- | --- | --- | --- |
| No baseline hearing impairment | “No hearing impairment observed at frequencies below 4,000 Hz” | “Hearing impairment observed but with a hearing threshold less than or equal to 40 dB HL at frequencies below 4,000 Hz” | “Hearing impairment with a threshold greater than 40 dB HL at frequencies below 4,000 Hz (hearing impairment in the speech hearing range)” |
| Baseline mild to moderate hearing impairment | “No hearing threshold shift at 2 consecutive frequencies below 4,000 Hz” | “Hearing threshold shift that is not greater than 15 dB at 2 consecutive frequencies below 4,000 Hz” | “Hearing threshold shift of greater than 15 dB at 2 consecutive frequencies below 4,000 Hz” |

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.10.1-5"></a>

### Dosage modifications for ataxia or fatigue

> “In patients with severe ataxia or fatigue associated with LEMBAZ treatment, consider reducing the LEMBAZ dosage”
> “If the LEMBAZ dosage is decreased due to severe ataxia or fatigue and the ataxia or fatigue becomes mild or resolves, then consider increasing the LEMBAZ dosage.”
> “Subsequently, if the ataxia or fatigue worsens in severity, then consider decreasing LEMBAZ dosing.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.10.1-6"></a>

### Missed doses

> “If one or more LEMBAZ doses are missed, restart LEMBAZ treatment as soon as possible, maintaining the 2-week interval between intrathecal administrations thereafter.”
> “Do not administer an extra LEMBAZ dose to compensate for a missed dose.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
